Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter ... While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for ...

Angina Pectoris Drugs Market Size and ForecastThe global angina pectoris drugs market is poised for substantial growth over ...

The COVID-19 vaccine continues to save lives, proving the vaccination strategy paid off and was a worthwhile national ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

This estimation was drawn from an analysis of data from consumer advocacy Public Citizen and Imperial College London that had been conducted by the international non-profit Oxfam. Pfizer has not ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals ...

Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker Pol Vandenbroucke – chief medical officer of the Hospital Business Unit at Pfizer – for his views on how data and patient ...